To:

Head of Paediatric Medicines
European Medicines Agency

Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Actives substances(s): Tafluprost

Invented name: Taflotan

Latest Decision number(s): 1) P/0132/2012 2) P/0216/2015 3) P/0159/2016 4) P/0061/2017

Corresponding PIP number(s): 1) EMEA-001187-PIP01-11 2) EMEA-001187-PIP01-11-M02 3) EMEA-001187-PIP01-11-M03 4) EMEA-001187-PIP01-11-M04

Date of initial marketing authorisation granted: 7 May 2008

Date of authorisation of new indication, pharmaceutical form or route of administration:

Please note that development of the medicinal product above in the following **condition(s)/indication(s)**:

Reduction of elevated intraocular pressure in open angle glaucoma and ocular hypertension

☒ has been discontinued

☐ has been suspended/put on long-term hold (with possible re-start at a later time)

for the following reason(s): (tick all that apply)

☐ (possible) lack of efficacy in adults

☐ (possible) lack of efficacy in children

☐ (possible) unsatisfactory safety profile in adults

☐ (possible) unsatisfactory safety profile in children

☐ commercial reasons (please specify:)

☐ manufacturing / quality problems

☐ other regulatory action (please specify:) (e.g. suspension, revocation of M.A.)

☒ other reason (please specify: the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients)

Please add a brief description (max 2000 characters) of the reason(s) for the discontinuation / suspension:

There are already two prostaglandin analogues approved and indicated for the reduction of elevated intraocular pressure in the treatment of paediatric glaucoma, Xalatan (latanoprost) and Travatan

(travoprost). For this reason Santen is of the opinion that tafluprost does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

There have been no major variations or extensions to the tafluprost authorisations since the original grant 07MAY2008 that would have triggered the obligations of the Paediatric Regulation Article 7 or 8. Santen originally initiated the PIP for tafluprost on a voluntary basis. During the procedure for a preservative free formulation DE/H/5250/001/MR the BfArM (RMS) confirmed that there is no paediatric obligation for tafluprost.

Please note that if the PIP has been submitted as part of a marketing authorisation application in order to comply with the requirements of Article 7 of the Paediatric Regulation (as a condition of the validation of the respective application) and a marketing authorisation was granted based on this application, then there is a legal obligation to complete that PIP. The same applies if there has been a successful post-authorisation application, where the PIP was included in order to comply with the requirements of Article 8 of the Paediatric Regulation.

Please confirm if any of the above applies to the PIP in question:

Yes ☐ No ☒

If yes, it means that based on the Marketing Authorisation obtained at the end of that initial procedure or the successful post authorisation application, as applicable, you are obliged to complete that PIP. That obligation cannot be cancelled by a unilateral decision, including by withdrawing the MA. Such PIP must be completed, unless it is modified in agreement with the PDCO by removing all outstanding PIP measures or granting a full product specific waiver instead (upon relevant circumstances in accordance with the Paediatric Regulation). Non-completion of a binding PIP establishes noncompliance with the requirements of the Paediatric Regulation, which the European Medicines Agency has an obligation to report to the European Commission.

Name and signature of the PIP contact point:	Signature on file
Date:	08.02.2021

Contact for inquiries from interested parties:	Santen Oy
Telephone:	+35832848111
Email:	regulatoryaffairs@santen.com